PL3456340T3 - Antagonista receptora glp-1 do zastosowania w leczeniu hiperinsulinizmu wrodzonego - Google Patents

Antagonista receptora glp-1 do zastosowania w leczeniu hiperinsulinizmu wrodzonego

Info

Publication number
PL3456340T3
PL3456340T3 PL18201976.0T PL18201976T PL3456340T3 PL 3456340 T3 PL3456340 T3 PL 3456340T3 PL 18201976 T PL18201976 T PL 18201976T PL 3456340 T3 PL3456340 T3 PL 3456340T3
Authority
PL
Poland
Prior art keywords
glp
treatment
receptor antagonist
congenital hyperinsulinism
hyperinsulinism
Prior art date
Application number
PL18201976.0T
Other languages
English (en)
Inventor
Doris Stoffers
Diva D DE LEON
Charles Stanley
Original Assignee
The Trustees Of The University Of Pennsylvania
Children's Hospital Of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, Children's Hospital Of Philadelphia filed Critical The Trustees Of The University Of Pennsylvania
Publication of PL3456340T3 publication Critical patent/PL3456340T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL18201976.0T 2007-01-08 2008-01-08 Antagonista receptora glp-1 do zastosowania w leczeniu hiperinsulinizmu wrodzonego PL3456340T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87903307P 2007-01-08 2007-01-08

Publications (1)

Publication Number Publication Date
PL3456340T3 true PL3456340T3 (pl) 2022-08-22

Family

ID=39609282

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18201976.0T PL3456340T3 (pl) 2007-01-08 2008-01-08 Antagonista receptora glp-1 do zastosowania w leczeniu hiperinsulinizmu wrodzonego

Country Status (14)

Country Link
US (7) US9821031B2 (pl)
EP (4) EP3456340B1 (pl)
CY (1) CY1125273T1 (pl)
DK (1) DK3456340T3 (pl)
ES (4) ES2499390T3 (pl)
FI (1) FI4049673T3 (pl)
HR (1) HRP20220346T3 (pl)
HU (1) HUE058307T2 (pl)
LT (1) LT3456340T (pl)
PL (1) PL3456340T3 (pl)
PT (1) PT3456340T (pl)
SI (1) SI3456340T1 (pl)
TR (1) TR201900959T4 (pl)
WO (1) WO2008085982A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456340B1 (en) * 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
EP2817025A2 (en) * 2012-02-08 2014-12-31 Seneb Biosciences, Inc. Treatment of hypoglycemia
BR112016017402A2 (pt) * 2014-02-21 2017-10-17 Medimmune Ltd fusões anti-pcsk9~glp-1 e métodos para uso
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016141111A1 (en) * 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
PL3297654T3 (pl) * 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it) * 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
CN116606367A (zh) * 2022-05-31 2023-08-18 南京盛德瑞尔医药科技有限公司 长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US20040092443A1 (en) * 1996-08-06 2004-05-13 Yeda Research And Development Co., Ltd Long-acting exendins and exendin agonists
PT1137413E (pt) * 1998-12-10 2005-05-31 Agouron Pharma Antagonistas nao-peptidicos do receptor de glp-1 e metodos de utilizacao
US6903074B1 (en) 1999-06-04 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Neuromedin b and somatostatin receptor agonists
SE0004462D0 (sv) * 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
WO2002066062A2 (en) * 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
JP4398644B2 (ja) 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ＥｒｂＢ界面ペプチド擬態およびその使用方法
CN1162446C (zh) * 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
US7378385B2 (en) 2002-08-08 2008-05-27 University Of Cincinnati Role for GLP-1 to mediate responses to disparate stressors
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
MX2008015107A (es) 2006-05-26 2008-12-09 Amylin Pharmaceuticals Inc Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva.
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
US9314508B2 (en) 2008-07-08 2016-04-19 Novartis Ag Use of somatostatin analogs in control of hypoglycemia
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)

Also Published As

Publication number Publication date
US10987407B2 (en) 2021-04-27
ES2499390T3 (es) 2014-09-29
TR201900959T4 (en) 2019-02-21
FI4049673T3 (fi) 2026-03-13
EP2120994B1 (en) 2014-06-11
ES2908838T3 (es) 2022-05-04
WO2008085982A2 (en) 2008-07-17
US20190336584A1 (en) 2019-11-07
HRP20220346T3 (hr) 2022-09-02
EP2818181B1 (en) 2018-10-24
US20080269130A1 (en) 2008-10-30
ES2710948T3 (es) 2019-04-29
US9616108B2 (en) 2017-04-11
SI3456340T1 (sl) 2022-08-31
EP2120994A4 (en) 2011-09-28
US20250312420A1 (en) 2025-10-09
US10188702B2 (en) 2019-01-29
DK3456340T3 (da) 2022-03-21
EP2120994A2 (en) 2009-11-25
PT3456340T (pt) 2022-05-25
EP3456340B1 (en) 2022-02-16
US20210252110A1 (en) 2021-08-19
EP2818181A1 (en) 2014-12-31
US20180050095A1 (en) 2018-02-22
EP3456340A1 (en) 2019-03-20
US20100190700A1 (en) 2010-07-29
US9821031B2 (en) 2017-11-21
US20240082361A1 (en) 2024-03-14
WO2008085982A3 (en) 2008-11-20
CY1125273T1 (el) 2023-06-09
HUE058307T2 (hu) 2022-07-28
ES3065108T3 (en) 2026-05-04
EP4049673B1 (en) 2026-01-28
EP4049673A1 (en) 2022-08-31
LT3456340T (lt) 2022-05-10

Similar Documents

Publication Publication Date Title
IL207532A0 (en) Glp-1 receptor agonists and related phamaceutical ingredients for the treatment of cancer
ES3065108T3 (en) Glp-1 receptor antagonist for use in the treatment of post-prandial hypoglycemia or congenital hyperinsulinism
ZA201004227B (en) Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
IL205704A (en) Use of alpha adrenoceptor inhibitors in the preparation of a drug for the treatment of pig fever
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
IL249941A0 (en) Spiro-oxaindole substances and medical preparations containing them
PT2129654E (pt) Antagonistas do receptor de glucagina
PL2004654T3 (pl) Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy
IL195152A (en) Compounds for use in treating diseases of cell culture
IL212551A0 (en) Cxcr4 receptor compounds
ZA200904150B (en) Progesterone receptor antagonists
PL2137191T3 (pl) Antagoniści obwodowego receptora opioidowego i ich zastosowania
HRP20150661T1 (en) Peripheral opioid receptor and antagonists and uses thereof
IL201886A0 (en) Thromboxane receptor antagonist formulations for use in treating and preventing thrombosis
IL218823A0 (en) Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
SI2004654T1 (sl) Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
ZA201008538B (en) Treating psychological conditions using muscarinic receptor m1 antagonists
GB0719248D0 (en) Compounds and methods for pharmaceutical use
PL2134334T3 (pl) Kompozycja znieczulająca w postaci nanocząstek do miejscowego stosowania
ZA200900242B (en) Use of glucocorticoid receptor antagonists for treatment of infectious conditions
ZA201000802B (en) Process for the preparation of alfuzosin hydrochloride
EP2146576A4 (en) TREATMENT OF DOWN SYNDROME WITH BENZODIAZEPINE REACTANT AGONISTS
ZA200906849B (en) Mineralcorticoid receptor antagonists for the treatment of endomertriosis
HK1145499A (en) Bicyclic derivatives for use in the treatment of androgen receptor associated conditions